文献速递泌尿系感染

延长治疗剂量抗生素疗程与低剂量预防用药治疗围绝经期及绝经后女性复发性非复杂性尿路感染的比较

Extended Treatment-dose Antibiotic Therapy vs Low-dose Prophylaxis for the Management of Recurrent Uncomplicated Urinary Tract Infections in Peri- and Post-menopausal Women.
PubMed 文献 · Urology · 2024-12-20

回顾性队列研究纳入246例复发性非复杂性尿路感染女性,比较1个月治疗剂量抗生素(n=43)与≥3个月低剂量预防用药(n=203)在12个月内症状性培养阳性尿路感染的风险;前者发生率34.9% vs 后者59.6%(P<.01),校正混杂因素后aOR 0.42(95%CI 0.20,0.89),作者认为该回顾性数据初步提示延长治疗剂量可能带来治疗获益并减少累积抗生素剂量与疗程,需随机试验进一步评估。

要点

  • 治疗剂量抗生素1个月组12个月内复发性尿路感染发生率为34.9%,低于低剂量预防≥3个月组的59.6%(P<.01)。
  • 多变量logistic回归校正潜在混杂因素后,治疗剂量组后续尿路感染风险仍显著降低(aOR 0.42;95%CI 0.20,0.89)。
  • 作者认为这些回顾性数据初步提示延长治疗剂量可能带来治疗获益并减少累积抗生素剂量与疗程,需随机试验进一步评估。

核心结论

  • 接受1个月治疗剂量抗生素的女性12个月内后续尿路感染风险显著低于接受≥3个月预防性抗生素的女性。
  • 这些回顾性数据初步提示延长治疗剂量抗生素可能提供治疗获益,同时减少总体累积抗生素剂量和疗程。
  • 作者认为这一创新方法需在随机试验中进一步评估。

研究设计与样本

  • 回顾性队列研究,纳入2018年1月1日至2020年10月1日期间就诊的急性非复杂性尿路感染成年女性,符合复发性尿路感染标准(6个月内≥2次或1年内≥3次)。
  • 患者接受两种方案之一:1个月治疗剂量抗生素治疗,或最多7天治疗剂量抗生素后接≥3个月低剂量预防性抗生素。
  • 排除复杂性尿路感染患者,共纳入246例患者。
  • 主要结局为12个月内一次或以上症状性、培养证实的尿路感染;采用多变量logistic回归在校正潜在混杂因素后评估主要结局差异。

主要发现

  • 接受延长治疗剂量抗生素组(n=43)1年内后续尿路感染发生率为34.9%,标准预防剂量≥3个月组(n=203)为59.6%,两组差异有统计学意义(P<.01)。
  • 在多变量logistic回归校正潜在混杂变量后,治疗剂量组后续尿路感染风险仍显著降低(aOR 0.42;95%CI 0.20,0.89)。

临床怎么用

  • 作者认为这些回顾性数据初步提示延长治疗剂量抗生素可能提供治疗获益,同时减少总体累积抗生素剂量和疗程。
  • 作者认为这一创新方法需在随机试验中进一步评估。

局限性

  • 原文未报告局限性,但作者在结论中自述这些为回顾性数据,仅初步提示可能获益,并明确需随机试验进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess treatment efficacy over 1year in women with recurrent urinary tract infection (UTI) receiving extended treatment-strength antibiotics compared to standard low-dose prophylactic antibiotic regimens. METHODS: A retrospective cohort study of adult women presenting with acute uncomplicated UTI between January 1, 2018 and October 1, 2020 meeting recurrent UTI criteria (≥2 in 6months or ≥3 in 1year). Women were offered either: (1) treatment-strength antibiotic therapy for 1month; or (2) up to 7days of treatment-strength antibiotics followed by ≥3-month of low-dose prophylactic antibiotics. We excluded those with complicated UTI. The primary outcome was one or more symptomatic, culture-proven UTIs within 12months. Multivariable logistic regression assessed differences in the primary outcome while controlling for potential confounders. RESULTS: Among the 246 patients, women receiving extended treatment dose antibiotics (n=43) had a significantly lower risk of experiencing subsequent UTI within 1year when compared to those receiving standard prophylactic dosing for ≥3-month (n=203) (rate 34.9% vs 59.6%; P<.01). This significant risk reduction was maintained in logistic regression analyses while controlling for potentially confounding variables (aOR 0.42; 95% CI 0.20, 0.89). CONCLUSION: Women treated with a 1-month course of treatment-strength antibiotics had a significantly lower risk of subsequent UTI within 12months compared to women receiving ≥3-month of prophylactic antibiotics. These retrospective data preliminarily suggest that extended treatment-strength antibiotic dosing may provide therapeutic benefit while reducing overall cumulative antibiotic dose and duration. This innovative approach warrants further evaluation in randomized trials.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Luchristt D, Siddiqui NY, Bruton Y, et al. Extended Treatment-dose Antibiotic Therapy vs Low-dose Prophylaxis for the Management of Recurrent Uncomplicated Urinary Tract Infections in Peri- and Post-menopausal Women. Urology. 2024. PMID: 39710076. doi:10.1016/j.urology.2024.12.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。